GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediWound Ltd (NAS:MDWD) » Definitions » EV-to-FCF

MediWound (MediWound) EV-to-FCF : -7.43 (As of May. 25, 2024)


View and export this data going back to 2014. Start your Free Trial

What is MediWound EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, MediWound's Enterprise Value is $125.79 Mil. MediWound's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-16.93 Mil. Therefore, MediWound's EV-to-FCF for today is -7.43.

The historical rank and industry rank for MediWound's EV-to-FCF or its related term are showing as below:

MDWD' s EV-to-FCF Range Over the Past 10 Years
Min: -18.45   Med: -5.78   Max: 7.37
Current: -7.43

During the past 13 years, the highest EV-to-FCF of MediWound was 7.37. The lowest was -18.45. And the median was -5.78.

MDWD's EV-to-FCF is ranked worse than
100% of 372 companies
in the Biotechnology industry
Industry Median: 8.36 vs MDWD: -7.43

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), MediWound's stock price is $16.39. MediWound's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.770. Therefore, MediWound's PE Ratio for today is At Loss.


MediWound EV-to-FCF Historical Data

The historical data trend for MediWound's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediWound EV-to-FCF Chart

MediWound Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.61 -10.38 -5.82 -5.19 -3.46

MediWound Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.19 -7.30 -5.06 -5.69 -3.46

Competitive Comparison of MediWound's EV-to-FCF

For the Biotechnology subindustry, MediWound's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MediWound's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MediWound's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where MediWound's EV-to-FCF falls into.



MediWound EV-to-FCF Calculation

MediWound's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=125.789/-16.929
=-7.43

MediWound's current Enterprise Value is $125.79 Mil.
MediWound's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MediWound  (NAS:MDWD) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

MediWound's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=16.39/-0.770
=At Loss

MediWound's share price for today is $16.39.
MediWound's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.770.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


MediWound EV-to-FCF Related Terms

Thank you for viewing the detailed overview of MediWound's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


MediWound (MediWound) Business Description

Traded in Other Exchanges
Address
42 Hayarkon Street, Yavne, ISR, 8122745
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. Its first biopharmaceutical product, NexoBrid removes dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns also referred to as severe burns. NexoBrid is currently in clinical development in North America and is in the process of preparing its Biologics License Application. The company derives its revenue from the United States.